

22 January 2026

Osteopore expands orthopaedic business into Hong Kong

Highlights

- Osteopore expands its orthopaedic business into Hong Kong through an exclusive distribution agreement with Hong Kong-based MontsMed Hong Kong Company Limited (MontsMed).
- The business will initially focus on the orthopaedic trauma reconstruction market, which is the key market segment where Osteopore's devices has the highest likelihood of application.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of an exclusive agreement with MontsMed Hong Kong Company Limited (MontsMed) for the introduction of its custom and off-the-shelf orthopaedic products into Hong Kong.

The business will initially focus on the orthopaedic trauma reconstruction market, which is the key market segment where Osteopore's devices has the highest likelihood of application. Based on data published by the Hospital Authority (HA)¹, a Hong Kong statutory body established under the Hospital Authority Ordinance in 1990, there were approximately 106,000 new cases in orthopaedic and traumatology in 2024.

¹ https://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10008&Lang=ENG&Dimension=100&Parent_ID=10004

The Asia Pacific bone graft and substitutes market was estimated to be USD 662m in 2024, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.2% from 2025 to 2030, driven by increasing prevalence of orthopaedic disorders and musculoskeletal injuries².

Although Hong Kong is a relatively small market, it holds strategic importance to China as a potential gateway to the Greater Bay Area. The potential benefits include regulatory harmonisation initiatives that facilitate cross-border use of medical devices and collaborative innovation across the region's extensive healthcare infrastructure³.

Osteopore introduced its range of orthopaedic products in Europe⁴ (custom only), Singapore and Vietnam⁵ (custom and off-the-shelf) in recent years, and has seen encouraging adoption from the orthopaedic community.

Key terms:

- 3-year distribution agreement with the option of a 1-year extension subject to mutual agreement
- Territory assigned: Hong Kong
- Business area: Orthopaedics

² <https://www.grandviewresearch.com/industry-analysis/asia-pacific-bone-grafts-substitutes-market>

³ <https://www.bayarea.gov.hk/gbais/tc/development/medical-co-operation/allowing-designated-healthcare-institutions-in-the-greater-bay-area-to-use-hong-kong-registered-drugs-and-medical-devices/>

⁴ ASX announcement "Osteopore secures EU market approvals for custom implants", 9 Apr 2025.

⁵ ASX announcement "Osteopore secures Singapore and Vietnam market approvals", 27 Mar 2024.

Commenting on the commercial expansion of orthopaedics into Hong Kong, CEO Dr Yujing Lim, said:

"The expansion of our orthopaedic business into Hong Kong is the latest in a series of planned commercial execution in the region.

"We are delighted to work with MontsMed, a key player in the Hong Kong orthopaedic ecosystem through their complementary solutions, to bring this product to the market", said Dr Lim.

Commenting on the partnership with Osteopore, MontsMed CEO Timothy Kong, said:

"We are a company that focuses on introducing innovative products to our network of surgeons. Osteopore's product fits this profile and has good potential application in a number of orthopaedic trauma reconstruction and tumour cases.

"We look forward to having meaningful conversations with our surgeons about this new and innovative method of bone reconstruction", said Mr. Kong.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About MontsMed Hong Kong Company Limited

MontsMed was founded in 2008 as an international pharmaceutical company incorporated in Hong Kong, and starting to shift its business attention specifically towards medical device in 2011.

We formed our operations base in Shanghai, China, where offices are established in major cities throughout Greater China, (Hong Kong, Taiwan, Beijing and Shanghai, China.) We are focused on the Asian Market and set Greater China as our priority.

MontsMed Builds lasting partnership with premium Medical Device Companies around the world to ensure their long-term success in the selected Asian Market.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.



No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

For personal use only

